A monoclonal antibody YX5 targeting human interleukin-8 and its application
By constructing an anti-IL-8 phage antibody library to screen and produce monoclonal antibody YX5, the problem of difficulty in screening and producing antagonistic antibodies against human interleukin-8 in the prior art was solved, and effective diagnosis of abnormal IL-8 diseases and Treatment, especially in tumor suppression, showed significant effects.
Patent Information
- Application Number
- CN202211499540.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-28
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-11-28
AI Technical Summary
Existing technologies are difficult to effectively screen and produce antagonistic monoclonal antibodies against human interleukin-8 (IL-8)-mediated diseases, resulting in poor diagnosis and treatment of IL-8-mediated diseases.
By constructing an anti-IL-8 phage antibody library, the monoclonal antibody YX5 that can specifically bind to human interleukin-8 was screened, and the antibody was produced on a large scale through genetic engineering and protein expression technology for use in abnormally related diseases of IL-8. Diagnosis and treatment.
The specific diagnosis and treatment of human interleukin-8 abnormal expression diseases has been achieved, especially in diseases such as tumors, which effectively inhibit IL-8-mediated cell chemotactics and tumor growth.
Smart Images

Figure CN115850472B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of preparation and application of human interleukin-8 monoclonal antibody, and specifically relates to a monoclonal antibody YX5 targeting human interleukin-8 and application thereof. Background Art
[0002] Interleukin-8 (IL-8), also known as CXCL8, belongs to the CXC subtype and is the earliest discovered chemotactic cytokine. IL-8 is divided into two subgroups, α and β. The initial translation product of IL-8 is 99 amino acids, which are cleaved into 72 amino acids in monocytes and macrophages, with a molecular weight of 8KDa active substances. IL-8 is mainly secreted by monocytes and macrophages, and its function is to recruit and activate neutrophils, promote inflammatory response and cell killing. In addition, tumor cells, fibroblasts, endothelial cells, etc., under the action of pro-inflammatory factors such as IL-1β, tumor necrosis factor α, and lipopolysaccharide, affect the proliferation, invasion, metastasis of tumor cells and the formation of tumor blood vessels through autocrine or paracrine.
[0003] IL-8 exerts its effects by binding to IL-8 receptors. IL-8 has two receptors, namely CXCR1 (IL-8RA) and CXCR2 (IL-8RB). These two receptors have 77% homology and are both G protein-coupled receptors. Because of the structural differences at the N-terminus, the two receptors have different affinities with IL-8, and CXCR1 has a higher affinity with IL-8. In normal tissue cells, CXCR1 first binds to granulocyte chemoattractant protein 2 (GCP-2) to form a complex, and then binds to IL-8 to exert its effects; CXCR2 has a lower affinity with IL-8. In addition to IL-8, CXCR2 can also bind to multiple ligands such as CXCL1, 2, 3, 5, and 7. IL-8 has obvious chemotaxis and functional activation effects on neutrophils, and can also induce chemotaxis of CD4+ and CD8+ T cells, and participates in the development of many diseases and tissue damage, such as rheumatoid arthritis, psoriasis, ischemia-reperfusion syndrome (including myocardial infarction and multiple organ failure), glomerulonephritis and other infectious diseases; IL-8 binding to receptors can promote the occurrence and development of tumors by activating multiple downstream signaling pathways such as PI3K / Akt, PLC / PKC and MAPK. Therefore, screening IL-8 antagonistic monoclonal antibodies can effectively treat IL-8-mediated diseases.
[0004] Using IL-8 as the immunogen, rabbits were immunized and an anti-IL-8 phage antibody library was constructed, which can effectively screen antibodies that antagonize IL-8. Through genetic engineering and protein expression technology, antagonistic IL-8 antibodies can be produced on a large scale for the diagnosis and treatment of IL-8 abnormality-related diseases. Summary of the invention
[0005] The first object of the present invention is to provide a specific monoclonal antibody against human interleukin-8. The antibody can be used for diagnosis and treatment of diseases caused by abnormal expression of IL-8.
[0006] YX5, a monoclonal antibody against human interleukin-8,
[0007] YX5 heavy chain variable region nucleic acid sequence:
[0008] GGTTCCACTGGTGACCAGGAGCAGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACACCCCTG
[0009] ACACTCACCTGCACCGTCTCTGGATTCTCCCTCAATAACTATGCAATGAGCTGGGTCCGCCAGGCTCCA
[0010] GGGAAGGGGCTGGAATACATCGGAGTCATCGGCTCTGATAATATTCCATACTACGCGACCTGGGCGAAA
[0011] GGCCGATTCGCCATCTCCAAAACCTCGACCAGGGTGGATCTGAAAATCACCAGTCCGACAACCGAGGAC
[0012] ACGGCCACCTATTTCTGTGCCAGCGGATATGTTGGGTGATGATAGATATAACATCTGGGGCCCAGGCACCCTCGTCACCGTCTCTTCA, see SEQ NO.1;
[0013] YX5 light chain variable region nucleic acid sequence:
[0014] GGTTCCACTGGTGACGCCGACATTGTGCTGACCCAGACTGCATCCCCCGTGTCTGCGGCTATTGGAGGC
[0015] ACAGTCACCATCAATTGCCAGTCCAGTCAGAGTGTTTATAGTAACAACTACTTATCCTGGTATCAGCAG
[0016] AAACCAGGGCAGCCTCCCAAGCTCCTGATCTATGCTGCATCCACTCTGGCATCTGGGGTCCCATCGCGG
[0017] TTCAAGGGCAGTGGATCTGGGACACAGTTCACTCTCACCATCAGCGACGTGCAGTGTGACGATGCTGCC
[0018] ACTTACTACTGTGCAGGCGCTTATAGTAATGATAGTGATGATGGTTTCGGCGGAGGGACCAAGCTGGAGATCAAA, see SEQ NO.2.
[0019] The monoclonal antibody YX5 against human interleukin-8 of the present invention,
[0020] YX5 heavy chain CDR sequence:
[0021] The amino acid sequence of CDRH1 is GFSLNNYA, see SEQ NO.3;
[0022] The amino acid sequence of CDRH2 is IGSDNIP, see SEQ NO.4;
[0023] The amino acid sequence of CDRH3 is ASGYVGDDRYNI, see SEQ NO.5;
[0024] YX5 light chain CDR sequence:
[0025] The amino acid sequence of CDRL1 is QSVYSNNY, see SEQ NO.6;
[0026] The amino acid sequence of CDRL2 AAS is shown in SEQ NO.7;
[0027] The amino acid sequence of CDRL3 is AGAYSNDSDDG, see SEQ NO.8.
[0028] Furthermore, the amino acid sequence of the heavy chain variable region of the monoclonal antibody YX5 against human interleukin-8 is:
[0029] GSTGDQEQLEESGGRLVTPGTPLTLTCTVSGFSLNNYAMSWVRQAPGKGLEYIGVIGSDNIPYYATWAKGRFAISKTSTRVDLKITSPTTEDTATYFCASGYVGDDRYNIWGPGTLVTVSS, see SEQ NO.9; YX5 light chain variable region amino acid sequence:
[0030] GSTGDADIVLTQTASPVSAAIGGTVTINCQSSQSVYSNNYLSWYQQKPGQPPKLLIYAASTLASGVPSRFKGSGSGTQFTLTISDVQCDDAATYYCAGAYSNDSDDGFGGGTKLEIK, see SEQ NO.10.
[0031] Furthermore, the antibody molecule includes but is not limited to: immunoglobulin, Fab, (Fab')2 or single-chain antibody.
[0032] The second objective of the present invention is to provide the use of the monoclonal antibody YX5 against human interleukin-8 for preparing a preparation for diagnosing diseases with abnormal expression of human interleukin-8.
[0033] The third object of the present invention is to provide the application of the monoclonal antibody YX5 against human interleukin-8 for preparing a drug for treating diseases related to abnormal expression of human interleukin-8.
[0034] Furthermore, the diseases associated with abnormal expression of human interleukin-8 include tumors.
[0035] The present invention uses the antigen human interleukin-8 to screen out antibodies against human interleukin-8, obtains heavy chain variable region and light chain variable region sequences that can bind to human interleukin-8 through sequencing, assembles the heavy chain variable region with the Fc fragment of human IgG1, and simultaneously expresses the antibody heavy chain and light chain in mammalian cells to express humanized anti-human interleukin-8 antibodies. Through in vitro experiments, the anti-human interleukin-8 monoclonal antibodies screened by the present invention can specifically bind to human interleukin-8, and can be used to detect or treat diseases caused by abnormal expression of human interleukin-8. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 IL-8 gene cloning;
[0037] Figure 2 After purification, IL-8 was detected by SDS-PAGE electrophoresis;
[0038] Figure 3 Anti-IL8 antibody heavy chain variable region gene cloning;
[0039] Figure 4 Anti-IL8 antibody light chain variable region gene cloning;
[0040] Figure 5 Gene splicing of the heavy and light chain variable regions of anti-IL8 antibodies;
[0041] Figure 6 Identification of anti-IL8 phage positive clones;
[0042] Figure 7 ELISA identification of the phage library in the fifth round of screening;
[0043] Figure 8 The antibody heavy and light chains were connected to pcDNA3.4 and identified by PCR;
[0044] Fig. 9 The purified product of antibody YX5 was detected by SDS-PAGE electrophoresis;
[0045] Fig.10 Anti-IL8 antibody inhibits neutrophil chemotaxis;
[0046] Fig.11 Anti-IL8 antibody inhibits HCT116 growth in vivo. DETAILED DESCRIPTION
[0047] The present invention is further described below in conjunction with specific embodiments, but will not be limited to the present invention.
[0048] The IL-8 protein used in the examples of the present invention was prepared in the laboratory.
[0049] The method for constructing the phage antibody library of the present invention is referred to: Antony S. Dimitrov (ed.), Generation and Selection of Rabbit Antibody Libraries by Phage Display, 2009, Therapeμtic Antibodies: Methods and Protocols, vol. 525, 101-128.
[0050] Example 1
[0051] 1. Preparation of IL-8 protein: Human monocyte cDNA was used as a template, and primers IL-8F and IL-8R were used to clone the IL-8 fragment, which was then introduced into the pGEX-4T-1 vector (Miaoling, P0001). The successfully constructed pGEX-4T-1-IL-8 was screened and expressed under IPTG induction conditions, and the IL-8 protein was purified.
[0052] The specific steps include:
[0053] 1. Cloning of IL-8 fragment
[0054] Dilute monocyte cDNA 10-fold
[0055] (1) The system is prepared as shown in Table 1:
[0056] Table 1
[0057] cDNA 2μl IL-8F 4μl IL-8R 4μl <![CDATA[ddH2O]]> 40μl PrimerSTAR (purchased from TAKARA) 50μl Total 100μl
[0058] Note: Primers for cloning IL8 gene
[0059] IL8-F: GTTCCGCGTGGATCCCCGGAAGAAGGTGCAGTTTTGCCAAG, see SEQ NO.11;
[0060] IL8-R: TCGAGTCGACCCGGGAATTTCATGAATTCTCAGCCCTCTTCA, see SEQ NO. 12.
[0061] (2) Reaction conditions are shown in the table below
[0062] Table 2
[0063] Step 1 98℃ 15s Step 2 98℃ 10s Step 3 55℃ 5s Step 4 72℃ 5s Go to Step 2x34 Step 5 72℃ 1m 30s Step 6 4℃ Forever
[0064] (3) Electrophoresis
[0065] Take 25 μl and perform 1% agarose gel electrophoresis to determine whether the target band is amplified, which is about 240 bp in size (see Figure 1 ).
[0066] (4) The 240 bp band was cut out and recovered using QIAquick Gel Extraction Kit (QIAGEN, 28706) to measure the concentration.
[0067] 2. Ligation and transformation of IL-8 fragment and vector pGEX-4T-1
[0068] Use Beijing Jinsha Biotechnology Co., Ltd. Uniclone one step seamless cloning kit, catalog number SC612
[0069] (1) Connection
[0070] System Configuration
[0071] Table 3
[0072] Components Purpose Reorganization 2X Uniclone seamless cloning Mix 5ul Linearization of pGEX-4T-1 1ul IL-8 fragment 3ul <![CDATA[ddH2O]]> 1ul
[0073] Reaction conditions
[0074] 50℃,15min
[0075] (2) Conversion
[0076] Take 2.5ul of the product from step (1) and add it to 50ul DH5α, place on ice for 30min, heat shock at 42°C for 90s, place on ice for 2min, add 1ml LB medium, and culture at 37°C, 220rpm for 1h. Take 100ul and spread it evenly on a plate containing ampicillin resistance, and culture it in a 37°C incubator overnight.
[0077] (3) Identification of positive clones
[0078] Single clones from step (2) were selected and identified by colony PCR using primers IL-8F / IL-8R. Positive clones were sent to a sequencing company for further sequencing and identification, and clones with correct sequences were retained.
[0079] 3. IL-8 expression and purification
[0080] (1) Pick a single clone and add it to 10 ml of LB liquid culture medium containing ampicillin resistance, and culture it at 37°C, 220 rpm overnight.
[0081] (2) Inoculate 100 ml of blank LB liquid medium containing ampicillin resistance with 1% of the bacterial solution from step (1), and culture overnight at 37°C and 220 rpm. When the OD600 reaches 0.6, add 0.2 mmol / L IPTG to induce for 4 h.
[0082] (3) After induction, pour the bacterial solution into a 50 ml centrifuge tube and centrifuge at 4000 rpm for 15 min. Discard the supernatant and add 10 ml of balancing solution (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) to resuspend the bacteria. Ultrasonicate until the bacterial solution is clear.
[0083] (4) Transfer the disrupted bacterial suspension to a centrifuge tube and centrifuge at 15,000 g at 4°C for 20 min. Take the supernatant and filter it through a 0.45 μm filter. Place the filtrate on ice.
[0084] (5) Equilibrate the Glutathlone Beads 4FF gravity column (Changzhou Tiandi Renhe Biotechnology Co., Ltd., Catalog No. SA010005) with 10-fold equilibration solution, add the supernatant from step (4), and allow the sample to pass through the column. Repeat 4 times.
[0085] (6) Add 15 times the equilibration solution to wash the column.
[0086] (7) Add 5 volumes of elution buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 10 mM reduced glutathione, pH 7.4) to elute the protein.
[0087] (8) The obtained target protein was concentrated using a 10Kd ultrafiltration tube and the buffer was replaced with 10 mM PBS.
[0088] (9) Determination of protein concentration of concentrated IL-8 and SDS-PAGE detection (see Figure 2 )
[0089] 2. IL-8 immunization of rabbits
[0090] (1) First immunization: 500ul IL-8 (1mg) was mixed with 500ul Freund's complete adjuvant and injected subcutaneously at multiple points on the back of 2-month-old New Zealand white rabbits.
[0091] (2) Every 2 weeks, 500ul IL-8 (1mg) was mixed with 500ul Freund's incomplete adjuvant.
[0092] Multiple injections were given subcutaneously on the back of New Zealand white rabbits, with immunizations repeated 3 times.
[0093] 3. Construction of phage antibody library
[0094] After the immunization, the New Zealand white rabbits were killed, the spleens were removed, the mononuclear cells were separated, the total RNA was extracted, and the cDNA was reverse transcribed. The heavy chain variable region and light chain variable region fragments were amplified using the heavy chain variable region and light chain variable region degenerate primers. The antibody heavy chain variable region and light chain variable region were randomly spliced and connected to the phage vector, and transformed into XL1-Blue bacteria (purchased from Yuwei Biotechnology Co., Ltd.), and assembled into a phage antibody display library in the presence of helper phage VSCM13 (purchased from NTCC National Type Culture Collection).
[0095] The specific steps include:
[0096] 1. Isolation of monocytes
[0097] Human peripheral blood lymphocyte separation medium (LTS1077-1, Tianjin Haoyang Biological Products Technology Co., Ltd.) was used to separate mononuclear cells.
[0098] (1) Preparation of cell suspension: Place the spleen on a cell sieve and place it in a culture dish with culture medium. Use a 2.5 ml syringe plunger to gently squeeze until the spleen is completely crushed. Transfer the cell suspension into a 15 ml centrifuge tube.
[0099] (2) Centrifuge the 15 mL centrifuge tube containing the cell suspension at 100 g for 10 min.
[0100] (3) Transfer the upper cell suspension into a 15 ml centrifuge tube containing an equal volume of lymph separation fluid. Use a pipette to carefully draw up the cell suspension and add it to the surface of the separation fluid. Centrifuge at 500-1100 g (1800 rpm) for 10 min, with an acceleration of 5 and a deceleration of 4.
[0101] (4) After centrifugation, the centrifuge tube is divided into four layers from top to bottom; the second layer is a ring-shaped milky white lymphocyte layer.
[0102] (5) Carefully transfer the second layer of circular milky white lymphocytes into a new 15 mL centrifuge tube using a pipette. Add 10 mL of PBS to the resulting centrifuge tube and mix the cells.
[0103] (6) 1800 rpm, centrifugation for 10 min, acceleration 5, deceleration 4.
[0104] (7) Discard the supernatant and add 5 ml of red blood cell lysis buffer to each 15 ml centrifuge tube. Mix slightly and let stand at room temperature for 5 min.
[0105] (8) 1800 rpm, centrifugation for 10 min, acceleration 5, deceleration 4.
[0106] (9) Discard the supernatant and resuspend the cells in 10 mL of PBS.
[0107] (10) 1800 rpm, centrifugation for 10 min, acceleration 5, deceleration 4.
[0108] (11) Discard the supernatant and precipitate the mononuclear cells.
[0109] 2. Total RNA Extraction
[0110] The obtained mononuclear cells were divided into 5 × 10 6 0.75 ml Trizol (Thermo Fisher) was added to each cell to extract total RNA, and then 1 μg RNA was taken from each cell and 18 RNAs were mixed in equal amounts.
[0111] (1) 5x10 6 Add 0.75 ml Trizol per cell.
[0112] (2) Mix up and down several times and incubate on ice for 5 min to ensure that the cells are fully lysed.
[0113] (3) Centrifuge at 12,000 rpm at 4°C for 10 minutes and transfer the supernatant to a clean centrifuge tube.
[0114] (4) Add 0.2 ml of chloroform to 1 ml of Trizol and mix well.
[0115] (5) Incubate on ice for 2-3 min.
[0116] (6) Centrifuge at 12000 rpm at 4°C for 15 min.
[0117] (7) Transfer the supernatant aqueous phase to a clean centrifuge tube.
[0118] (8) Add an equal volume of isopropanol to the supernatant and mix well.
[0119] (9) Incubate at room temperature for 10 min and centrifuge at 12,000 rpm at 4°C for 10-15 min.
[0120] (10) Discard the supernatant and keep the precipitate.
[0121] (11) Add 1 ml of 75% ethanol to wash the precipitate.
[0122] (12) Centrifuge at 12000 rpm at 4°C for 5 minutes.
[0123] (13) Discard the supernatant as much as possible.
[0124] (15) Dry at room temperature for 5-10 minutes. No liquid is visible on the tube wall.
[0125] (16) Add 20-50 μl of RNAse-free water to dissolve the RNA.
[0126] (17) Take 1 μl of RNA for electrophoresis and determine the RNA concentration.
[0127] (18) Store RNA in aliquots at -80°C to avoid repeated freezing and thawing.
[0128] 3. Synthesis of cDNA
[0129] 5 μg of RNA was taken and a cDNA synthesis kit (K1612, Thermo fisher) was used.
[0130] (1) Take 5 μg of RNA and synthesize cDNA.
[0131] (2) 10 μl RNA / primer mixtμre system as shown in Table 4 below, including:
[0132] Table 4
[0133]
[0134]
[0135] (3) Incubate at 65°C for 5 min and place on ice for 1 min.
[0136] (4) Add other reagents according to Table 5 to prepare cDNA Synthesis Mix for the next reaction.
[0137] Table 5
[0138] System components 1 Response 10xRT buffer 2μl <![CDATA[25mM MgCl2]]> 4μl 0.1M DTT 2μl RNase O ΜT (40Μ / μl) 1μl Superscript III RT (200Μ / μl) 1μl
[0139] (5) Add 10 μl of cDNA Synthesis Mix to the RNA / primer mixture, mix gently, centrifuge, and react according to the conditions in Table 6 below:
[0140] Table 6
[0141] Step 1 50℃ 50min Step 2 85℃ 5min Cool on ice and centrifuge briefly Step 3 RNaseH 1μl Step 4 37℃ 20min
[0142] (6) The cDNA product was packaged and stored at -20°C.
[0143] 4. Amplification of antibody heavy chain variable region (VH) and light chain variable region (VL)
[0144] The synthesized cDNA was diluted 10-fold and used as a template for amplifying the heavy chain variable region and the light chain variable region.
[0145] (1) The system is prepared as shown in Table 7, taking VH as an example:
[0146] Table 7
[0147]
[0148]
[0149] (2) Reaction conditions are shown in the table below
[0150] Table 8
[0151] Step 1 98℃ 15s Step 2 98℃ 10s Step 3 55℃ 5s Step 4 72℃ 5s Go to Step 2x34 Step 5 72℃ 1m 30s Step 6 4℃ Forever
[0152] (3) Electrophoresis
[0153] Take 10 μl and perform 1% agarose gel electrophoresis to determine whether the target band is amplified, which is about 400 bp in size (see Figure 3 ).
[0154] (4) All amplified VH were mixed in equal amounts, 0.1 volumes of 3 M sodium acetate and 2.2 volumes of ethanol were added, mixed well, and placed at -20°C overnight.
[0155] (5) Centrifuge at 16,000 g for 15 min at 4°C, remove the supernatant, rinse with 1 ml of 70% ethanol (at room temperature), dry at room temperature, add 200 μl of water for re-dissolution, and perform gel electrophoresis with 1% gel.
[0156] (6) The 400 bp band was cut out and recovered using QIAquick Gel Extraction Kit (QIAGEN, 28706) to measure the concentration.
[0157] (7) Amplification and recovery of VL were performed according to steps (1) to (6). The results are shown in Figure 4 .
[0158] (8) Adjust the nucleic acid concentration of VH and VL after purification to a final concentration of 100 ng / μl and store at -20°C.
[0159] 5. Amplification of Cκ-pelB
[0160] (1) Use vectors pCκ and pCL (purchased from add gene) (100 ng / μl) as templates to amplify Cκ-pelB and CL-pelB
[0161] Taking the amplification of Cκ-pelB as an example, see Table 9.
[0162] Table 9
[0163] pCκ 10μl HCK (sequence see the above reference) 60μl Pelb (sequence see the above reference) 60μl <![CDATA[ddH2O]]> 370μl PrimerSTAR 500μl Total 1000μl
[0164] (2) Reaction conditions are shown in Table 10
[0165] Table 10
[0166] Step 1 98℃ 15s Step 2 98℃ 10s Step 3 55℃ 5s Step 4 72℃ 5s Go to Step 2x34 Step 5 72℃ 1m 30s Step 6 4℃ Forever
[0167] (3) Take 10 μl of the product for electrophoresis detection, and the band size is about 400 bp.
[0168] (4) All amplified Cκ-pelB were mixed, 0.1 volumes of 3 M sodium acetate and 2.2 volumes of ethanol were added, mixed well, and placed at -20°C overnight.
[0169] (5) Centrifuge at 16,000 g for 15 min at 4°C, remove the supernatant, rinse with 1 ml of 70% ethanol (at room temperature), dry at room temperature, add 200 μl of water for re-dissolution, and perform gel electrophoresis using 1% gel.
[0170] (6) The 400 bp band was cut out and recovered using QIAquick Gel Extraction Kit (QIAGEN, 28706) to measure the concentration.
[0171] (7) Dilute the purified Cκ-pelB to a final concentration of 100 ng / μl and store at -20°C.
[0172] (8) Amplify CL-pelB according to steps (1) to (7), except that the amplification template pCκ is replaced with pCL.
[0173] 6. Rab Vκ / Rab Cκ / CL / Rab VH fusion
[0174] (1) Mix different amounts of VL, VH, and Ck-pelB according to Table 11.
[0175] VL concentration: 100 ng / μl, VH concentration: 100 ng / μl, Cκ-pelB concentration: 100 ng / μl
[0176] Table 11
[0177] V L 10μl VH 10μl Ck-pelB 10μl Primerstar Mix 500μl <![CDATA[H2O]]> 470μl Total 1000μl
[0178] (2) Reaction conditions are shown in Table 12
[0179] Table 12
[0180] Step 1 98℃ 15s Step 2 98℃ 10s Step 3 50℃ 5s Step 4 72℃ 5s Step 5 Go to Step 2x10 Step 6 72℃ 1m 30s Step7 4℃ Forever
[0181] (3) Amplification of Rab VL / Rab Cκ / Rab VH, see Table 13Table 13
[0182] Splicing products 50μl C-5'SFIVL (sequence see the above reference) 4μl c-3'sfivh (sequence see the above reference) 4μl <![CDATA[ddH2O]]> 17μl PrimerSTAR 25μl Total 100μl
[0183] (4) Amplification conditions are shown in Table 14
[0184] Table 14
[0185]
[0186]
[0187] (5) Electrophoresis detection
[0188] Take 10μl of PCR product and perform electrophoresis detection. The target gene band size after fusion is about 1.2Kb. (See Figure 5 )
[0189] (6) Add 0.1 volume of 3 M sodium acetate and 2.2 volume of ethanol to all amplified Rab VL / Rab Cκ / Rab VH, mix well, and place at -20°C overnight.
[0190] (7) Centrifuge at 16,000 g for 15 min at 4°C, remove the supernatant, rinse with 1 ml of 70% ethanol (at room temperature), dry at room temperature, add 200 μl of water for re-dissolution, and perform gel electrophoresis using 1% gel.
[0191] (8) The 1.2 Kb band was cut out and recovered using QIAquick Gel Extraction Kit (QIAGEN, 28706) to measure the concentration.
[0192] (9) Dilute the purified Rab VL / Rab CK / Rab VH nucleic acid to a final concentration of 150 ng / μl and store at -20°C.
[0193] (10) Fusion of Rab Vλ / Rab CL / Rab VH was carried out according to steps (1) to (9).
[0194] 7. SfiI digestion of Rab Vκ / Rab Cκ / CL / Rab VH and RabVλ / RabCL / Rab VH
[0195] Taking Rab Vκ / Rab Cκ / CL / Rab VH digestion as an example
[0196] (1) Enzyme digestion system see Table 15
[0197] Table 15
[0198] human Vκ / human Cκ / CL / human VH(150ng / μl) 200 μl 10Xbuffer 30μl <![CDATA[H2O]]> 60μl SfiI 40u / μl 10μl
[0199] (2) Incubate in a 50°C water bath for 3 h.
[0200] (3) Perform electrophoresis using 1% gel, cut out the 1.2 kb band, and recover it using QIAquick Gel Extraction Kit (QIAGEN, 28706).
[0201] (4) After detection of SfiI digestion, the Rab VL / Rab Ck / Rab VH fragments were recovered, the concentration was adjusted to 50 ng / μl, and stored at -20°C.
[0202] (5) Enzyme digestion of Rab Vλ / Rab CL / Rab VH, following steps (1)-(4).
[0203] 8. Digest pC3C with SfiI (the vector was purchased from add gene)
[0204] (1) Enzyme digestion system see Table 16
[0205] Table 16
[0206] pC3C 1μg / μl 50μl 10Xbuffer 30μl <![CDATA[H2O]]> 208μl SfiI 40u / μl 12μl
[0207] (2) Incubate in a 50°C water bath for 3 h.
[0208] (3) When electrophoresis is performed using a 1% gel, two bands will be cut out, one 3.5 kb and one 1.2 kb.
[0209] (4) Use QIAquick Gel Extraction Kit (QIAGEN, 28706) to recover the 3.5 Kb vector backbone.
[0210] (5) After Sfi digestion, the concentration of the recovered vector backbone was adjusted to 100 ng / μl.
[0211] 9. Ligation of pC3C (SfiI) and Rab VL / human Cκ / Rab VH (SfiI)
[0212] (1) Connection system see Table 17
[0213] Table 17
[0214] 100ng / μl pC3C after SfiI digestion 1.5μl 50ng / μl human VL / human Cκ / human VH after SfiI digestion 2μl 10XT4 DNA ligase buffer 2μl <![CDATA[H2O]]> 13.5μl T4 DNA ligase 2000u / μl 1μl
[0215] The control group is shown in Table 18
[0216] Table 18
[0217] 100ng / μl pC3C after SfiI digestion 1.5μl 10XT4 DNA ligase buffer 2μl <![CDATA[H2O]]> 15.5μl T4 DNA ligase 2000u / μl 1μl
[0218] (2) Incubate at 16°C overnight.
[0219] (3) Combine all ligation reactions and add 1 / 10 volume of 3M sodium acetate solution.
[0220] (4) Add 2.2 times the volume of pre-cooled anhydrous ethanol, mix well, and precipitate at -20°C overnight.
[0221] (5) Centrifuge at 16000g, 4°C for 30 min and carefully discard the supernatant.
[0222] (6) Add 70% ethanol to gently wash the precipitate, centrifuge at 16,000 g, 4°C for 5 min, and discard the supernatant.
[0223] (7) Dry at room temperature.
[0224] (8) Dissolve with an appropriate amount of water. Usually, 1 μl of ddH2O is used to fully dissolve the reaction mixture. Store at -20°C.
[0225] (9) Ligate pC3C (SfiI) and Rab Vλ / Rab CL / Rab VH according to steps (1) to (8).
[0226] 10. Transformation of ligation product into XL1-Blue
[0227] (1) Place the XL1-Blue electroporated cells on ice for 10 min to dissolve.
[0228] (2) Take 19 μl of the precipitated and concentrated ligation product and add it to a 1.5 ml centrifuge tube. Place it on ice and add 300 μl of XL1-Blue electroporation competent medium to mix well. Quickly transfer it to a 2 mm electroporation cup and place it on ice for 1 min.
[0229] (3) Electric shock conditions: 2.5KV, 4ms
[0230] (4) After electroporation, quickly add 5 ml (1 ml + 2 ml + 2 ml) of SOC medium, transfer to a 50 ml conical bottom centrifuge tube, and culture at 37°C, 250 rpm for 1 hour. Take 2 μl of bacterial solution and add it to 198 μl of LB, and evenly spread it on an LB plate containing 100 μg / μl carbenicillin, and culture it at 37°C overnight for calculation of transformation efficiency and colony PCR identification positive rate. PCR results are shown in Figure 6 .
[0231] (5) Add 10 ml SB medium, 3 μl 100 μg / μl carbenicillin, and 30 μl 5 μg / μl tetracycline. Incubate at 37°C, 250 rpm for 1 h.
[0232] (6) Add 4.5 μl of 100 μg / μl carbenicillin and continue incubation at 37°C, 250 rpm for 1-4 h.
[0233] (7) The cultured bacteria were transferred to a 500 ml culture flask, and 84 ml of SB medium, 42.5 μl of 100 μg / μl carbenicillin, 170 μl of 5 μg / μl tetracycline, and 1 ml of VCMS13 helper phage (10 11 -10 12 pfu / ml), 37℃, 275rpm, 90min.
[0234] (8) Add 140 μl of 50 μg / μl kanamycin and culture overnight at 37°C, 275 rpm.
[0235] (9) Centrifuge at 3000 g, 4°C for 15 min.
[0236] (10) Precipitation of phage
[0237] Transfer the supernatant (200ml) to a clean 500ml centrifuge tube, add 8g PEG-8000 and 6g NaCl, and place at 37℃, 300rpm, for 5min to promote dissolution. Place on ice for 30min-1h. Centrifuge at 15000g, 4℃ for 15min. Discard the supernatant, place the centrifuge bottle upside down on the filter paper and let it dry for 10min, and carefully remove the excess liquid. Resuspend the phage in 2ml TBS containing 1% BSA (mix up and down with a pipette), centrifuge at 16000g, 4℃ for 5min, pass the supernatant through a 0.22μm filter (Millipore), and transfer to a 2ml centrifuge tube. For short-term storage, it can be directly placed on ice, or 0.01 times the volume of 2% sodium azide can be added and placed at 4℃. For long-term storage, add 1 times the volume of glycerol and store at -20℃.
[0238] 2. Phage antibody library screening: Taking IL-8 phage antibody screening as an example
[0239] Using a 96-well plate coated with IL-8 protein, five rounds of screening were performed, and then monoclonal clones were selected to identify IL-8 specific antibodies.
[0240] 1. Antigen coating
[0241] (1) Add IL-8 to carbonate buffer at a concentration of 2 μg / ml.
[0242] (2) Add 50 μl of IL-8 to each well of Corning high-protein adsorption ELISA 96-well plate and place at 4°C overnight;
[0243] (3) Discard the supernatant, add 5% skim milk powder (200 μl / well), and incubate at 37°C for 1 h;
[0244] (4) Discard the supernatant and wash five times with 0.05% TBST.
[0245] 2. IL-8 antibody screening
[0246] (1) Dilute the phage antibody library 10 times with 2% skim milk powder, take two 96-well microwells coated with IL-8 antigen, add 100 μl of the diluted phage, and place at 37°C for 1 hour.
[0247] (2) Discard the supernatant, wash five times with 0.05% TBST, add 100 μl of 100 mM glycine, and place at 37°C for 15 min while constantly pipetting, and add 9 μl of 1 M Tris.
[0248] (3) Add the phage eluted in step (2) to 2 ml of XL1-Blue bacteria and leave at room temperature for 15 min.
[0249] (4) Add 6 ml of SB medium, 1.6 μl of 100 μg / μl carbenicillin, and 12 μg of 5 μg / μl tetracycline, and culture at 37°C, 250 rpm for 1 h.
[0250] (5) Add 2.4 μl of 100 μg / μl carbenicillin and continue culturing for 1 h;
[0251] (6) Add 1 ml of helper phage VCSM13 (10 11 -10 12 pfu / ml), transferred to a 500 ml culture flask, added with 91 ml SB medium, 46 μl 100 μg / μl carbenicillin, 184 μl 5 μg / μl tetracycline, cultured at 37°C, 250 rpm for 1.5 h, added with 140 μl 50 μg / μl kanamycin, and cultured at 37°C, 250 rpm overnight.
[0252] (7) Phage antibody concentration: centrifuge the bacterial solution from the previous step to remove the bacteria, collect the supernatant (100 ml); add 4g PEG-8000 and 3g NaCl, place at 37°C, 300rpm, for 5 minutes to promote dissolution. Place on ice for 30 minutes to 1 hour. Centrifuge at 15000g, 4°C for 15 minutes. Discard the supernatant, place the centrifuge bottle upside down on the filter paper and let it dry for 10 minutes, and carefully remove the excess liquid. Resuspend the phage in 2ml TBS containing 1% BSA (mix up and down with a pipette), centrifuge at 16000g, 4°C for 5 minutes, filter the supernatant through a 0.22μm filter membrane (Millipore), and transfer to a 2ml centrifuge tube. For short-term storage, it can be directly placed on ice, or 0.01 times the volume of 2% sodium azide can be added and placed at 4°C. For long-term storage, add 1 times the volume of glycerol and store at -20°C.
[0253] (8) Take the phage from step (7) and perform five rounds of screening according to steps (1) to (7).
[0254] (9) ELISA identification of the antibody library after five rounds of screening:
[0255] 1) ELISA 96-well plate, each well coated with 100 ng of IL-8;
[0256] 2) Add 100 μl of phage (diluted 10 times with 2% skim milk powder) and incubate at 37°C for 1 h;
[0257] 3) Wash 5 times with 0.05% TBST;
[0258] 4) Add 100 μl of anti-M13-HRP antibody (purchased from Beijing Sino Biological Technology Co., Ltd.) diluted 2000 times with 5% skim milk powder and incubate at 37°C for 1 h;
[0259] 5) Wash 5 times with 0.05% TBST;
[0260] 6) Add 100 μl TMB and color for 5 min in the dark;
[0261] 7) Add 50 μl 1M H2SO4 to terminate the reaction.
[0262] 8) Measure the absorbance at 450 nm using an ELISA reader.
[0263] Results Figure 7 and Table 19.
[0264] Table 19 ELISA identification of the 5th round of screening phage library
[0265]
[0266] 3. Identification of IL-8 monoclonal antibodies
[0267] (1) Take the IL-8 phage from the fifth round of screening and dilute it by 10 -7 , add 1 μl to 200 μl XL1-Blue bacteria and leave at room temperature for 15 min;
[0268] (2) All the bacteria from step (1) were spread on LB individual culture medium containing 100 μg / ml carbenicillin and cultured at 37°C overnight;
[0269] (3) Select 200 single clones and add them to 6 ml of liquid LB medium containing 10 μg / ml tetracycline and 100 μg / ml carbenicillin. Cultivate at 37°C, 250 rpm for 4 hours. Take a small amount of bacterial solution and perform bacterial culture.
[0270] Liquid PCR was used for identification, and clones with a band size of about 1200 bp were selected.
[0271] The colony PCR amplification system is shown in Table 20:
[0272] Table 20
[0273] Bacterial liquid 0.5μl VHSEQ (sequence see the above reference) 0.2μl vlseq (sequence see the above reference) 0.2μl <![CDATA[ddH2O]]> 4.1μl PrimerSTAR 5μl Total 10μl
[0274] Colony PCR reaction conditions are shown in Table 21:
[0275] Table 21
[0276] Step 1 98℃ 3min Step 2 98℃ 10s Step 3 50℃ 5s Step 4 72℃ 15s Step 5 Go to Step 2x34 Step 6 72℃ 1m 30s Step7 4℃ Forever
[0277] (4) The positive clone solution of step (3) was evenly divided into two parts, and 3 μl of helper phage VCSM13 (10 11 -10 12 pfu / ml), placed at room temperature for 20 min, added with 2.1 μl of 50 μg / μl kanamycin, and the other portion was cultured overnight at 37°C and 250 rpm without any substance;
[0278] (5) The bacteria with helper phage were centrifuged at 4000 rpm for 10 min, the supernatant was transferred to a clean centrifuge tube, the supernatant was diluted 10 times, 100 μl was added to the ELISA plate coated with IL-8, incubated at 37°C for 1 h, washed 5 times with 0.05% TBST, 2000-fold diluted anti-phage HRP-labeled antibody (purchased from Beijing Yiqiao Shenzhou Biotechnology Co., Ltd.) was added, incubated at 37°C for 1 h, washed 5 times with 0.05% TBST, 100 μl TMB was added, color developed for 2 min, 50 μl 1 M H2SO4 was added to terminate the reaction, and the absorbance was measured at 450 nm using an enzyme reader. The clones with an absorbance 2.1 times higher than the control were positive clones.
[0279] (6) Select the positive clones in step (5) without adding helper phage, extract the plasmids, and sequence them to obtain the heavy chain variable region and light chain variable region sequences.
[0280] 3. Expression and activity identification of fully humanized antibodies
[0281] 1. Construction of fully humanized vector
[0282] (1) Designing corresponding primers based on the obtained antibody heavy chain variable region or light chain variable region sequence, and adding secretory signal peptides to the N-termini of the heavy chain and light chain, and adding the Fc fragment of IgG1 to the C-terminus of the heavy chain after amplification;
[0283] (2) Homologous recombination of the heavy chain variable region and the light chain variable region into the pcDNA3.4 vector. Figure 8 )(pcDNA3.4 vector was purchased from Wuhan Miaoling Biotechnology Co., Ltd.)
[0284] 2. Expression of fully humanized antibodies
[0285] (1) Using an endotoxin removal kit (purchased from OMEGA), extract the corresponding heavy chain expression vector and light chain expression vector respectively;
[0286] (2) When the confluency of 293T cells (purchased from Wuhan Pronocell Life Science Co., Ltd.) reached 80%, PEI was used for transfection;
[0287] (3) 12 h after transfection, the medium was replaced with serum-free protein expression medium and cultured at 37°C, 5% CO2 for 7 days;
[0288] (4) Antibodies were purified using protein A / G filler. Results are shown in Fig. 9 .
[0289] 3. Identification of fully humanized antibody activity
[0290] Taking IL-8 antibody activity identification as an example
[0291] (1) ELISA identification
[0292] The obtained antibody was adjusted to a concentration of 1 mg / ml, diluted 2000 times with 5% skim milk powder, added to the ELISA well coated with IL-8 antigen, incubated at 37°C for 1 hour, washed 5 times with 0.05% TBST, added 2000 times anti-human Fab-HRP secondary antibody (purchased from Beijing Solaibao Biotechnology Co., Ltd.) diluted with 5% skim milk powder, incubated 1 hour at 37°C, washed 5 times with 0.05% TBST, added 100 μl TMB, color developed for 2 minutes, added 50 μl 1M H2SO4 to terminate the reaction, and measured the absorbance at 450 nm using an enzyme reader. The results are shown in Table 22.
[0293] Table 22 ELISA identification of YX5 binding to IL-8 after purification
[0294]
[0295] (2) Using YX5 as the fixed antibody and YX5, YX20, and YX40 as the detection antibody combination to detect IL-8 protein as follows:
[0296] The ELISA sandwich method was used for detection. The monoclonal fully humanized antibody YX5 was coated on the ELISA plate, and the antigen IL-8 was added. The selected YX5, YX20, and YX40 biotin-labeled antibodies (biotin brand: Thermo, item number: VF300852) were added, and different combinations were made. HRP-labeled streptavidin (brand: ThermoFisher, item number: VE302151) was added to detect the color. The darker the color, the stronger the IL-8 antigen capture ability, and it also shows that the antibody pair is suitable for the detection of IL-8 antigen. The blank control is to add no antibody, only HRP-labeled streptavidin.
[0297] The specific operations are as follows:
[0298] 1) ELISA 96-well plate, each well coated with 100 ng of YX5 antibody;
[0299] 2) Add 100 μl IL-8 (250 ng / ml) and incubate at 37°C for 1 h;
[0300] 3) Wash 5 times with 0.05% TBST;
[0301] 4) Add YX5, YX20, or YX40 biotin-labeled antibodies diluted 2000 times with 5% skim milk powder and incubate at 37°C for 1 h;
[0302] 5) Wash 5 times with 0.05% TBST;
[0303] 6) Add 5% skim milk powder diluted 5000 times with HRP-labeled streptavidin and incubate at room temperature for 10 min;
[0304] 7) Wash 5 times with 0.05% TBST;
[0305] 8) Add 100 μl TMB and color for 5 min in the dark;
[0306] 9) Add 50 μl 1M H2SO4 to terminate the reaction.
[0307] 10) Measure the absorbance at 450 nm using an ELISA reader.
[0308] The results are shown in Table 23.
[0309] Table 23 Sandwich method identification of antibody pairs for detecting IL8
[0310]
[0311]
[0312] Note: Vertical columns are coating phase, horizontal columns are detection phase, and OD450 absorbance value.
[0313] (3) Neutrophil chemotaxis inhibition
[0314] 1) Neutrophils were isolated from human peripheral blood (Tianjin Haoyang, TBD LZS11131), and the neutrophil concentration was adjusted to 5X10 using 1640 6 Pieces / ml;
[0315] 2) A 24-well Trans-well plate (Corning Costar, 3415) with a pore size of 3 μm was used. The experiment was divided into three groups: blank group, 400 μl of blank 1640 was added to the lower chamber; positive control group, 400 μl of 1640 containing 10 nM IL8 was added to the lower chamber; experimental group, 400 μl of 1640 containing 10 nM IL8 and 5 μg / ml IL8 antibody was added to the lower chamber; all three groups, 200 μl (concentration 5×10 6 / ml) of neutrophils;
[0316] 3) Place the culture medium at 5% CO2 and 37°C for 2 h, discard the upper chamber, and count the number of cells in the lower chamber using a cell counter.
[0317] The results are shown in Table 24 and Table 25. Fig.10 .
[0318] Table 24 Anti-IL8 antibodies inhibit neutrophil chemotaxis to IL8
[0319]
[0320] Table 25 Inhibition of neutrophil chemotaxis by anti-IL8 antibodies (unit: %)
[0321] Duplicate hole 1 Duplicate hole 2 Duplicate hole 3 YX5 91.04 112.31 117.91
[0322] (4) Anti-IL8 antibody inhibits tumor
[0323] 1) The nude mice were divided into two groups, the experimental group and the control group, with 3 mice in each group. Before the experiment, 100ul 1X10 6 HCT116 tumor cells (colon tumor cells);
[0324] 2) After 3 days, each nude mouse in the control group was intraperitoneally injected with 200ul PBS, and each nude mouse in the experimental group was intraperitoneally injected with 200ul PBS containing 500ug anti-IL8 antibody, once every 3 days;
[0325] 3) After 4 rounds of injection, on the 3rd day after the last injection, the nude mice were killed, the tumors were removed and weighed. The results are shown in Table 26 and Fig.11 .
[0326] Table 26 Anti-IL8 Antibody Inhibition of Tumors (Unit: g)
[0327] serial number 1 2 3 control 0.27 0.26 0.3 YX5 0.01 0.15 0.01
Claims
1. A monoclonal antibody YX5 against human interleukin-8, characterized in that: YX5 heavy chain variable region nucleic acid sequence: GGTTCCACTGGTGACCAGGAGCAGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACACCCCTGACACTCACCTGCACCGTCTCTGGATTCTCCCTCAATAACTATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAATACATCGGAGTCATCGGCTCTGATAATAT TCCATACTACGCGACCTGGGCGAAAGGCCGATTCGCCATCTCCAAAACCTCGACCAGGGTGGATCTGAAAATCACCAGTCCGACAACCGAGGACACGGCCACCTATTTCTGTGCCAGCGGATATGTTGGTGATGATAGATATAACATCTGGGGCCCAGGCACCCTCGTCACCGTCTCTTCA; YX5 light chain variable region nucleic acid sequence: GGTTCCACTGGTGACGCCGACATTGTGCTGACCCAGACTGCATCCCCCGTGTCTGCGGCTATTGGAGGCACAGTCACCATCAATTGCCAGTCCAGTCAGAGTGTTTATAGTAACAACTACTTATCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTATGCTGC ATCCACTCTGGCATCTGGGGTCCCATCGCGGTTCAAGGGCAGTGGATCTGGGACACAGTTCACTCTCACCATCAGCGACGTGCAGTGTGACGATGCTGCCACTTACTACTGTGCAGGCGCTTATAGTAATGATAGTGATGATGGTTTCGGCGGAGGGACCAAGCTGGAGATCAAA.
2. A monoclonal antibody YX5 against human interleukin-8, characterized in that: YX5 heavy chain CDR sequence: CDRH1 amino acid sequenceGFSLNNYA CDRH2 amino acid sequence IGSDNIP CDRH3 amino acid sequence ASGYVGDDRYNI; YX5 light chain CDR sequence: CDRL1 amino acid sequence QSVYSNNY CDRL1 amino acid sequence AAS CDRL1 amino acid sequence AGAYSNDSDDG.
3. The monoclonal antibody YX5 against human interleukin-8 according to claim 2, characterized in that: YX5 heavy chain variable region amino acid sequence: GSTGDQEQLEESGGRLVTPGTPLTLTCTVSGFSLNNYAMSWVRQAPGKGLEYIGVIGSDNIPYYATWAKGRFAISKTSTRVDLKITSPTTEDTATYFCASGYVGDDRYNIWGPGTLVTVSS; YX5 light chain variable region amino acid sequence: GSTGDADIVLTQTASPVSAAIGGTVTINCQSSQSVYSNNYLSWYQQKPGQPPKLLIYAASTLASGVPSRFKGSGSGTQFTLTISDVQCDDAATYYCAGAYSNDSDDGFGGGTKLEIK.
4. The use of the monoclonal antibody YX5 against human interleukin-8 according to any one of claims 1 to 3, characterized in that: Used for preparing preparations for treating colon tumors.
